Proglumide

Phase 2Small molecule

GGeorgetown University

Proglumide is one of 42 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerActive, not recruiting

Safety IssuesActive, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Safety IssuesPreclinical

Active, not recruiting

Competition

Competitive Landscape

306 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Medrol

Pfizer

Preclinical

1 2

Byetta

AstraZeneca

Preclinical

1 3

Proglumide

GGeorgetown University

Phase 2

1 4

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 5

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 7

Active Comparator

Moderna

Preclinical

1 8

Secretin-Ferring

Ferring

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Pancreatic Cancer

NCT05827055

Q4 2031

PreclinicalActive, not recruiting

Safety Issues

NCT05551858

Clinical

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma1 trial

Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma

Withdrawn·GGeorgetown University·Phase 1·NCT06017323

Pancreatic Cancer1 trial

Proglumide and Chemotherapy for Metastatic Pancreatic Cancer

Active, not recruiting·GGeorgetown University·Phase 2·NCT05827055·30 enrolled

Oral1 trial

Safety and Tolerability of Oral Proglumide for NASH

Completed·GGeorgetown University·Phase 1·NCT04152473·18 enrolled

Hepatic Impairment1 trial

Single-dose PK Assessment of Oral Proglumide in Those With Hepatic Impairment

Completed·GGeorgetown University·Phase 1·NCT04814602·11 enrolled

Safety Issues1 trial

A Phase 1/2 Trial to Test the Safety of a CCK Receptor Antagonist, Proglumide, in Management of Chronic Pancreatitis Symptoms and Pain for 12 to 24 Months

Active, not recruiting·GGeorgetown University·Preclinical·NCT05551858·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Proglumide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Proglumide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Proglumide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Georgetown University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGeorgetown University

Proglumide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2031

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma1 trial

Pancreatic Cancer1 trial

Oral1 trial

Hepatic Impairment1 trial

Safety Issues1 trial

References

Drug Info

Quick Facts

Related News